[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL405505A1 - Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3 - Google Patents

Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3

Info

Publication number
PL405505A1
PL405505A1 PL40550513A PL40550513A PL405505A1 PL 405505 A1 PL405505 A1 PL 405505A1 PL 40550513 A PL40550513 A PL 40550513A PL 40550513 A PL40550513 A PL 40550513A PL 405505 A1 PL405505 A1 PL 405505A1
Authority
PL
Poland
Prior art keywords
acid derivative
application
biological activity
diaminodicarboxylic acid
diaminodicarboxylic
Prior art date
Application number
PL40550513A
Other languages
Polish (pl)
Inventor
Katarzyna Koziak
Barbara Żyżyńska-Granica
Sławomir Filipek
Szymon Niewieczerzał
Bartosz Trzaskowski
Oliwia Zegrocka-Stendel
Małgorzata Dutkiewicz
Piotr Krzeczyński
Elżbieta Kaczmarek
Magdalena Winiarska
Original Assignee
Warszawski Uniwersytet Medyczny
Fundacja Na Rzecz Wspierania Rozwoju Polskiej Farmacji I Medycyny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny, Fundacja Na Rzecz Wspierania Rozwoju Polskiej Farmacji I Medycyny filed Critical Warszawski Uniwersytet Medyczny
Priority to PL40550513A priority Critical patent/PL405505A1/en
Priority to PL417876A priority patent/PL417876A1/en
Priority to PCT/IB2014/001939 priority patent/WO2015044761A1/en
Publication of PL405505A1 publication Critical patent/PL405505A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Wynalazek dotyczy zastosowania pochodnej kwasu diaminodikarboksylowego, którą stanowi kwas 2,9-diaminodekanodikarboksylowy w postaci izomeru optycznego, mieszaniny izomerów optycznych, w tym racematu, farmaceutycznie dopuszczalnej soli lub estru alkoholu alifatycznego, w leczeniu i zapobieganiu chorób, u podłoża których jest nadmierna produkcja interleukiny 15 i interleukiny 2, takich jak reumatoidalne zapalenie stawów, łuszczyca, zapalenie jelit, sarkoidoza, białaczki T-komórkowe lub odrzucanie przeszczepów.The invention relates to the use of a diaminodicarboxylic acid derivative, which is 2,9-diaminodecanedicarboxylic acid in the form of an optical isomer, a mixture of optical isomers, including a racemate, a pharmaceutically acceptable salt or ester of an aliphatic alcohol, in the treatment and prevention of diseases which are caused by excessive production of interleukin and interleukins 2, such as rheumatoid arthritis, psoriasis, enteritis, sarcoidosis, T-cell leukemia or transplant rejection.

PL40550513A 2013-09-30 2013-09-30 Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3 PL405505A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL40550513A PL405505A1 (en) 2013-09-30 2013-09-30 Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3
PL417876A PL417876A1 (en) 2013-09-30 2014-09-29 Applications of the derivative of diamine-dicarboxylic acid as the L-15 and IL-2 biologic activity inhibitor
PCT/IB2014/001939 WO2015044761A1 (en) 2013-09-30 2014-09-29 Diaminodecanedioic acid derivative as the inhibitor of il-15 and il-2 activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL40550513A PL405505A1 (en) 2013-09-30 2013-09-30 Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3

Publications (1)

Publication Number Publication Date
PL405505A1 true PL405505A1 (en) 2015-04-13

Family

ID=51947386

Family Applications (2)

Application Number Title Priority Date Filing Date
PL40550513A PL405505A1 (en) 2013-09-30 2013-09-30 Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3
PL417876A PL417876A1 (en) 2013-09-30 2014-09-29 Applications of the derivative of diamine-dicarboxylic acid as the L-15 and IL-2 biologic activity inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL417876A PL417876A1 (en) 2013-09-30 2014-09-29 Applications of the derivative of diamine-dicarboxylic acid as the L-15 and IL-2 biologic activity inhibitor

Country Status (2)

Country Link
PL (2) PL405505A1 (en)
WO (1) WO2015044761A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
CU23472A1 (en) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech ANTAGONIST PEPTIDE OF INTERLEUCINE-15
BRPI0708942A2 (en) * 2006-03-21 2011-06-14 Joyant Pharmaceuticals Inc apoptosis promoting compound, use and method of production thereof and pharmaceutical composition
CU23716A1 (en) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech ANTAGONIST PEPTIDE OF THE ACTIVITY OF INTERLEUCINA-15
JP5478082B2 (en) * 2009-01-20 2014-04-23 株式会社山田養蜂場本社 Interleukin-2 production inhibitor

Also Published As

Publication number Publication date
WO2015044761A1 (en) 2015-04-02
PL417876A1 (en) 2017-02-13

Similar Documents

Publication Publication Date Title
PH12017501921A1 (en) Novel compounds
MX2018015625A (en) COMPOUNDS AND COMPOSITIONS TO INHIBIT THE ACTIVITY OF SHP2.
CO2018011408A2 (en) Pyrimidine compounds as inhibitors of jak kinase
EA202091016A1 (en) PYRIMIDINE COMPOUND AS A JAK KINASE INHIBITOR
EA201591051A1 (en) ERK INHIBITORS AND THEIR OPTIONS
AR128259A2 (en) SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHILIC ELASTASE ACTIVITY
CR20190156A (en) Bipyrazole derivatives as jak inhibitors
EA201691442A1 (en) N-AZASPROCYCLOALKAN-SUBSTITUTED N-HETEROARRYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING SHP2 ACTIVITY
EA201391230A1 (en) COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS
MX2013001970A (en) PIRROLOPIRIMIDINE COMPOUNDS AND USES OF THE SAME.
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
ECSP18026386A (en) SALTS OF A PIM KINASE INHIBITOR
PH12019501362A1 (en) Polymorphs
UY35357A (en) REPLACED BICYCLIC DIHYDROPIRIMIDINONES AND ITS USE AS INHIBITORS OF THE ACTIVITY OF NORTHEAST ELASTASE
CO6612202A2 (en) Pde4 bicyclic heterparyl inhibitors
EA201790016A1 (en) PIRIDINO [1,2-a] PYRIMIDONE ANALOG USED AS PI3K INHIBITOR
PH12020550947A1 (en) Polymorphs
EA201790282A1 (en) SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR APPLICATION AS NEUTROFIL-ELASTASY ACTIVITY INHIBITORS
CO6630197A2 (en) New process
PL405506A1 (en) Application of the 7-aminocephalosporanic acid derivative as inhibitor biological activity of IL-15 and IL-2
PL405505A1 (en) Application of the diaminodicarboxylic acid derivative as inhibitor biological activity of IL-15 and IL-3
MX2017003016A (en) Pyridazinone derivatives as phosphoinositide 3-kinases inhibitors.
UA110882C2 (en) The pharmaceutical composition and a method of producing
UY33584A (en) NEW BENZAMIDA COMPOUNDS OF LRRK2 INHIBITORS
MX2015014702A (en) A compound for use in the treatment of comorbid anxiety disorder and depression disorder.

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)